RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin.
RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin.
复制标题
DOI:
10.1038/s12276-018-0078-1
复制
发表时间:
2018-04-27
影响因子:
12.8
通讯作者:
Lee HY
中科院分区:
文献类型:
--
作者:
Choe SR;Kim YN;Park CG;Cho KH;Cho DY;Lee HY
Rab coupling protein (RCP) aggravates cancer cell metastasis and has been implicated in various cancer patient outcomes. Recently, we showed that RCP induces Slug expression and cancer cell invasion by stabilizing the β1 integrin protein. In the present study, we demonstrated that FAK is implicated in RCP-induced EGFR phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. Ectopic expression of RCP induced FAK phosphorylation, which links β1 integrin with EGFR and participates in a positive regulation loop with EGFR. Interestingly, we observed for the first time that curcumin attenuates RCP-induced ovarian cancer cell invasion by blocking stabilization of β1 integrin and consequently inhibiting FAK and EGFR activation, providing potential biomarkers for ovarian cancer and therapeutic approaches for this deadly disease. Rab coupling protein (RCP)-induced tumor cell migration has been implicated in tumor pathophysiology and patient outcomes. Hoi Young Lee and colleagues at Konyang University in Daejeon, South Korea, have previously shown that RCP promotes ovarian cancer cell invasiveness by stabilizing cell adhesion receptors. In their latest study they find that RCP also increases the levels of two of its protein-binding partners and activates an important mediator of growth factor signaling, Focal Adhesion Kinase (FAK). Interestingly, treating ovarian cancer cells with curcumin, a natural compound extracted from the spice turmeric, not only blocked the effects of RCP on cell adhesion and FAK activation, it also potentiated the inhibitory effects of the chemotherapeutic agent doxorubicin on cell invasiveness. Further research will determine whether curcumin could be used to halt ovarian cancer progression.
登录
查看更多内容
DOI:
10.1155/2013/541695
发表时间:
2013
期刊:
Evidence-based complementary and alternative medicine : eCAM
影响因子:
--
作者:
Chen CC;Sureshbabul M;Chen HW;Lin YS;Lee JY;Hong QS;Yang YC;Yu SL
通讯作者:
Yu SL
影响因子:
4.7
作者:
Chen, Chi-Hau;Shyu, Ming-Kwang;Huang, Min-Chuan
通讯作者:
Huang, Min-Chuan
影响因子:
4.8
作者:
Lindsay, AJ;Hendrick, AG;McCaffrey, MW
通讯作者:
McCaffrey, MW
影响因子:
7.5
作者:
Mukherjee S;Mazumdar M;Chakraborty S;Manna A;Saha S;Khan P;Bhattacharjee P;Guha D;Adhikary A;Mukhjerjee S;Das T
通讯作者:
Das T
影响因子:
21.3
作者:
Nader, Guilherme P. F.;Ezratty, Ellen J.;Gundersen, Gregg G.
通讯作者:
Gundersen, Gregg G.